PT Medikaloka Hermina Tbk (ISX:HEAL) Research & Development: Rp0 Mil (TTM As of Mar. 2026)


ISX:HEAL PT Medikaloka Hermina Tbk ISX:HEAL
72 GF Score
Price Rp840.00
GF Value Rp1,577.62
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is PT Medikaloka Hermina Tbk Research & Development?

PT Medikaloka Hermina Tbk ISX:HEAL -0.59% 72 Research & Development is Rp0 Mil as of Mar. 2026. GuruFocus rates ISX:HEAL with a GF Score™ of 72/100 and a GF Value™ of Rp1,577.62 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. PT Medikaloka Hermina Tbk's Research & Development for the three months ended in Mar. 2026 was Rp0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was Rp0 Mil.

PT Medikaloka Hermina Tbk  (ISX:HEAL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

PT Medikaloka Hermina Tbk Research & Development Related Terms

PT Medikaloka Hermina Tbk Research & Development Historical Data

* Premium members only.

The historical data trend for PT Medikaloka Hermina Tbk's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Medikaloka Hermina Tbk Research & Development Chart

PT Medikaloka Hermina Tbk Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PT Medikaloka Hermina Tbk Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ISX:HEAL
72GF Score
PT Medikaloka Hermina Tbk ISX:HEAL
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PT Medikaloka Hermina Tbk Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of Rp0 Mil mean?
PT Medikaloka Hermina Tbk (ISX:HEAL) has a Research & Development of Rp0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on PT Medikaloka Hermina Tbk and its competitors.
Is PT Medikaloka Hermina Tbk's Research & Development too high?
PT Medikaloka Hermina Tbk's current Research & Development is Rp0 Mil. Overall, PT Medikaloka Hermina Tbk has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Medikaloka Hermina Tbk's Research & Development compare to HCA and THC?
PT Medikaloka Hermina Tbk's Research & Development of Rp0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on PT Medikaloka Hermina Tbk and its competitors. PT Medikaloka Hermina Tbk's current Research & Development is Rp0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Medikaloka Hermina Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Medikaloka Hermina Tbk (ISX:HEAL) is currently considered Significantly Undervalued. The stock's GF Value™ is Rp1,577.62, compared to a current price of Rp840.00 — trading 46.8% below its estimated fair value. The current Research & Development is Rp0 Mil. PT Medikaloka Hermina Tbk's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For PT Medikaloka Hermina Tbk (ISX:HEAL), the current Research & Development is Rp0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PT Medikaloka Hermina Tbk (ISX:HEAL) Overvalued in 2026?

Based on GuruFocus' analysis, PT Medikaloka Hermina Tbk stock appears to be undervalued. The current stock price of Rp840.00 is trading 46.8% below its estimated GF Value™ of Rp1,577.62. GuruFocus considers PT Medikaloka Hermina Tbk to be Significantly Undervalued.

Key valuation signals for ISX:HEAL:

  • Research & Development: Rp0 Mil
  • GF Value™: Rp1,577.62 vs. price of Rp840.00 (46.8% below fair value)
  • GF Score™: 72/100 with 5 warning signs

No single metric tells the full story. See the ISX:HEAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PT Medikaloka Hermina Tbk Business Description

Address Jalan Selangit B-10 Kavling No. 4, Hermina Tower, Kemayoran, Jakarta, IDN, 10610
PT Medikaloka Hermina Tbk is a private hospital group. It provides a range of medical services, including maternal and child health services, complex operating procedures, laboratory services, radiology facilities, and fertility treatments as well as general health services, pharmacies, diagnostic and emergency services. The company's geographical segment includes Kalimantan dan Sulawesi, Jawa, and Sumatera. It derives maximum revenue from the Jawa segment.
72GF Score

Get the complete analysis for ISX:HEAL

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Rp840.00
Price
Rp1,577.62
GF Value